ERBB2 and breast cancer: In the DESTINY-Breast04 phase III (NCT03734029) trial, 45 HER2-low advanced BC patients were treated with T-DXd, and T-DXd-related ILD occurred in 12.1% (10% grade 1 or 2, 1.3% grade 3 or 4, and 0.8% grade 5).16